NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 84 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $115,663 | -14.9% | 36,602 | +4.2% | 0.00% | – |
| Q2 2023 | $135,938 | +36.3% | 35,126 | -2.4% | 0.00% | – |
| Q1 2023 | $99,742 | +37.9% | 36,008 | -10.4% | 0.00% | – |
| Q4 2022 | $72,324 | +0.4% | 40,180 | +18.8% | 0.00% | – |
| Q3 2022 | $72,000 | -28.7% | 33,812 | -9.4% | 0.00% | – |
| Q2 2022 | $101,000 | -69.7% | 37,312 | -51.4% | 0.00% | – |
| Q1 2022 | $333,000 | +1413.6% | 76,731 | +1747.6% | 0.00% | – |
| Q4 2021 | $22,000 | -83.5% | 4,153 | -80.8% | 0.00% | – |
| Q3 2021 | $133,000 | +786.7% | 21,601 | +1340.1% | 0.00% | – |
| Q2 2021 | $15,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $16,298,000 | 8.49% |
| Madrona Venture Group, LLC | 6,020,770 | $31,188,000 | 5.89% |
| ArchPoint Investors | 1,449,551 | $7,509,000 | 2.23% |
| Ally Bridge Group (NY) LLC | 1,225,060 | $6,346,000 | 2.22% |
| Affinity Asset Advisors, LLC | 1,049,721 | $5,438,000 | 1.98% |
| Tikvah Management LLC | 1,231,835 | $6,381,000 | 1.78% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $10,360,000 | 0.82% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $1,356,000 | 0.74% |
| Perceptive Advisors | 18,222,302 | $94,390,000 | 0.73% |
| SPHERA FUNDS MANAGEMENT LTD. | 800,000 | $4,144,000 | 0.46% |